ArticleChemMedChem2021
A Quick Route to Multiple Highly Potent SARS-CoV-2 Main Protease Inhibitors*.
Open access · bronzeAbstract read
In one paragraph
Article in ChemMedChem, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 82 papers.
0numbers the graph read from it
0cells of the map it votes in
82citing papers in PubMed
2.5field-weighted citation impact, top 6% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
82 citing papers in PubMed, 130 citations in OpenAlex.
- Disulfide bond formation between Cys22 and Cys44 in SARS-CoV-2 main protease.Bioorganic & medicinal chemistry letters · 2026Article
- High-Throughput Screening Identifies Covalent Inhibitors with Unique Chemistry and Binding Modes for SARS-CoV‑2 Main Protease.JACS Au · 2026Article
- Nitrile-Based Inhibitors Targeting both SARS-CoV‑2 Main Protease and Human Cathepsin L.ACS medicinal chemistry letters · 2026Article
- Identification of Potential SARS-CoV-2 Main Protease (MPro) Inhibitors Through Pharmacophore Modeling, Molecular Docking, and Molecular Dynamics Simulation Approaches.International journal of molecular sciences · 2026Article
- Article
- Nicotine-Inspired, De Novo-Designed SARS-CoV-2 Main Protease Inhibitors Reveal Unique Chemistry for Covalently Conjugating Both Cysteine and Histidine Residues in the Catalytic Dyad.Journal of the American Chemical Society · 2026Article
- From vibrations to function: Spectroscopic detection and quantification of π-π stacking in drug-responsive protein complexes.Science advances · 2026Article
- From nicotine to SARS-CoV-2 antivirals with potent in vivo efficacy and a broad anti-coronavirus spectrum.Nature communications · 2026Article
- Regioselective multicomponent synthesis of α-boryl ureas: discovery of a potent main protease inhibitor.Organic & biomolecular chemistry · 2026Article
- Design and In Vitro Evaluation of Novel GC373-like SARS-CoV-2 Main Protease Inhibitors.Current issues in molecular biology · 2026Article
- Mutation-Induced Resistance of SARS-CoV-2 MInternational journal of molecular sciences · 2026Article
- Integrated computational screen and validation of thalidomide-based PROTACs targeting SARS-CoV-2 main protease.RSC medicinal chemistry · 2026Article
- Support Vector Machine Identification of Small Molecule Binders to an Understudied Allosteric Site of SARS-CoV-2 Mpro for Next-Generation PROTAC-Based Therapeutics.Archiv der Pharmazie · 2025Article
- Exploring covalent inhibitors of SARS-CoV-2 main protease: from peptidomimetics to novel scaffolds.Journal of enzyme inhibition and medicinal chemistry · 2025Review
- Discovery of a potent covalent inhibitor that unusually distorts the catalytic dyad of SARS-CoV-2 main protease.Journal of virology · 2025Article
- Computational and Experimental Study of the Conformational Variation of the Catalytic Residue His41 of the SARS-CoV-2 Main Protease.The journal of physical chemistry. B · 2025Article
- Article
- Research Progress on the Structure and Function, Immune Escape Mechanism, Antiviral Drug Development Methods, and Clinical Use of SARS-CoV-2 MMolecules (Basel, Switzerland) · 2025Review
- Covalent Proximity Inducers.Chemical reviews · 2025Review
- 3-chymotrypsin-like protease in SARS-CoV-2.Bioscience reports · 2024Review
22 more citing papers are in PubMed but not listed here.
Corrections and comments
- Update of
Authors and funding
22 authors at 5 institutions in 1 country.
Kai S YangDepartment of Chemistry, Texas A&M University, College Station, TX 77843-3255, USA.
Xinyu R MaDepartment of Chemistry, Texas A&M University, College Station, TX 77843-3255, USA.
Yuying MaDepartment of Chemistry, Texas A&M University, College Station, TX 77843-3255, USA.
Yugendar R AlugubelliDepartment of Chemistry, Texas A&M University, College Station, TX 77843-3255, USA.
Danielle A ScottDepartment of Chemistry, Texas A&M University, College Station, TX 77843-3255, USA.
Erol C VatanseverDepartment of Chemistry, Texas A&M University, College Station, TX 77843-3255, USA.
Aleksandra K DrelichDepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX 77555, USA.
Banumathi SankaranMolecular Biophysics and Integrated Bioimaging Berkeley Center for Structural Biology, Lawrence Berkeley National Laboratory, Berkeley, CA 94720, USA.
Zhi Z GengDepartment of Chemistry, Texas A&M University, College Station, TX 77843-3255, USA.
Lauren R BlankenshipDepartment of Chemistry, Texas A&M University, College Station, TX 77843-3255, USA.
Hannah E WardDepartment of Chemistry, Texas A&M University, College Station, TX 77843-3255, USA.
Yan J ShengDepartment of Chemistry, Texas A&M University, College Station, TX 77843-3255, USA.
Jason C HsuDepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX 77555, USA.
Kaci C KratchDepartment of Chemistry, Texas A&M University, College Station, TX 77843-3255, USA.
Baoyu ZhaoDepartment of Biochemistry and Biophysics, Texas A&M University, College Station, TX 77843, USA.
Hamed S HayatshahiDepartment of Pharmaceutical Sciences, UNT Health Science Center, Fort Worth, TX 76107, USA.
Jin LiuDepartment of Pharmaceutical Sciences, UNT Health Science Center, Fort Worth, TX 76107, USA.ORCID 0000-0002-7078-6534
Pingwei LiDepartment of Biochemistry and Biophysics, Texas A&M University, College Station, TX 77843, USA.
Carol A FierkeDepartment of Chemistry, Texas A&M University, College Station, TX 77843-3255, USA.
Chien-Te K TsengDepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX 77555, USA.
Shiqing XuDepartment of Chemistry, Texas A&M University, College Station, TX 77843-3255, USA.
Wenshe Ray LiuDepartment of Chemistry, Texas A&M University, College Station, TX 77843-3255, USA.
Texas A&M University · USThe University of Texas Medical Branch at Galveston · USUniversity of North Texas · USLawrence Berkeley National Laboratory · USTexas A&M Health Science Center · US
Funding
WRCE Nonhuman Primate CoreU54AI057156 · NIAID · UNIVERSITY OF TEXAS MEDICAL BR GALVESTON · PI WALKER, DAVID H · 2003 to 2013
$102.6MUser Training and OutreachP30GM124169 · NIGMS · UNIVERSITY OF CALIF-LAWRENC BERKELEY LAB · PI PAUL David ADAMS, Gregory L Hura · 2017 to 2026
$28.6MMolecular basis of viral DNA sensing through the cGAS-STING pathwayR01AI145287 · NIAID · TEXAS A&M AGRILIFE RESEARCH · PI Pingwei Li · 2019 to 2026
$2.5MStudying Reversible Histone Acylations in Nucleosome ContextsR01GM121584 · NIGMS · TEXAS A&M UNIVERSITY · PI LIU, WENSHE RAY · 2017 to 2020
$1.3MInflammatory Response and SARS Pathogenesis: An in vitro ModelR21AI072201 · NIAID · UNIVERSITY OF TEXAS MED BR GALVESTON · PI TSENG, CHIEN-TE K · 2007 to 2009
$633kEstablishment of a Transgenic Mouse Model for Middle East Respiratory Syndrome CoR21AI113206 · NIAID · UNIVERSITY OF TEXAS MED BR GALVESTON · PI TSENG, CHIEN-TE K · 2014 to 2015
$426kEnergy Office of Science User Facility DE-AC02-05CH11231Howard Hughes Medical InstituteNIAID NIH HHS R01 AI145287NIAID NIH HHS R21 AI072201NIAID NIH HHS R21 AI113206NIAID NIH HHS U54 AI057156NIGMS NIH HHS GM124169-01NIGMS NIH HHS P30 GM124169NIGMS NIH HHS R01 GM121584NIH HHSNIH HHS R01AI145287NIH HHS R01 GM121584Texas A&M University President's Excellence FundTexas A&M University Strategic Transformative Research ProgramTexas A&M University Translational Investment FundTexas A&M University X Grant MechanismWelch Foundation A-1715Welch Foundation A-1987
Abstract
The COVID-19 pathogen, SARS-CoV-2, requires its main protease (SC2M
Indexed as
A549 CellsAlanineAnimalsAntiviral AgentsCatalytic DomainChlorocebus aethiopsCoronavirus 3C ProteasesCysteineCysteine Proteinase InhibitorsHumansMicrobial Sensitivity TestsProtein BindingPyrrolidinonesSARS-CoV-2Vero Cells3C-like proteinase, SARS-CoV-2AlanineAntiviral AgentsCoronavirus 3C ProteasesCysteineCysteine Proteinase InhibitorsPyrrolidinones3C-like proteaseantiviralsCOVID-19main proteasereversible covalent inhibitorsSARS-CoV-2
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.